Theodore J Torphy

US Patent:

6369108, Apr 9, 2002

Filed:

Jun 28, 2000

Appl. No.:

09/582739

Inventors:

Theodore Torphy - Bryn Mawr PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31165

US Classification:

514567, 514363, 514364, 514381, 514530, 514531, 514538, 514615, 514619, 514646

Abstract:

A method for treating COPD is disclosed comprising administering compounds of Formula (I) wherein the terms R , R , X, X and Z are herein defined.

US Patent:

6555576, Apr 29, 2003

Filed:

Aug 31, 2001

Appl. No.:

09/914696

Inventors:

Richard Nieman - Philadelphia PA
Theodore J. Torphy - Bryn Mawr PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31275

US Classification:

514521, 514362, 514363, 514364, 514381, 514520, 514826

Abstract:

Methods of treating exercise-induced asthma using a PDE-4 inhibitor are disclosed.

US Patent:

6555583, Apr 29, 2003

Filed:

Aug 20, 2001

Appl. No.:

09/933455

Inventors:

Richard Nieman - Philadelphia PA
Anthony S Rebuck - Collegeville PA
Theodore J Torphy - Bryn Mawr PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 3119

US Classification:

514572, 514653

Abstract:

This invention relates to treating pulmonary diseases such as chronic obstructive pulmonary disease or asthma by administering a phosphodiesterase 4 inhibitor in combination with beta adrenergic bronchodilator.

US Patent:

6670394, Dec 30, 2003

Filed:

Aug 31, 2001

Appl. No.:

09/914703

Inventors:

Mary S. Barnette - West Chester PA
Theodore J. Torphy - Bryn Mawr PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31165

US Classification:

514520, 514362, 514363, 514364, 514381, 514382, 514521, 514522, 514530, 514531, 514538, 514567, 514615, 514619, 514646, 514826, 514851, 514885

Abstract:

This invention relates to a method for the prophylaxis of or for treating COPD by administering a PDE4 inhibitor which has a defined therapeutic ratio.

US Patent:

20020068351, Jun 6, 2002

Filed:

Sep 5, 2001

Appl. No.:

09/947305

Inventors:

George Livi - Havertown PA, US
Megan McLaughlin - Drexel Hill PA, US
Theodore Torphy - Bryn Mawr PA, US

Assignee:

SmithKline Beecham Corporation

International Classification:

C12Q001/68
G01N033/537
G01N033/53
G01N033/543
C07H021/04
C12N009/16
C12P021/02
C12N005/06

US Classification:

435/196000, 435/325000, 435/320100, 435/069100, 435/007920, 536/023200

Abstract:

Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low K, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IVmRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an 4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional 5-kb hPDE IVrelated mRNA species was detected in brain tissue. Expression of hPDE IVin a genetically-engineered PDE-deficient strain of the yeast resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low K(4.3 M) for cAMP, 2) high K( 3 mM) for cGMP, and 3) sensitivity to rolipram (K=0.085 M), a selective inhibitor of PDE IV. Recombinant hPDE IValso bound [H] R-rolipram saturably and with a high affinity. Analysis of [H] R-rolipram binding data revealed curvilinear Scatchard plots, suggesting the presence of two non-interacting high affinity rolipram binding sites (K=0.4 and 6 nM) or a negatively cooperative interaction among multiple binding sites. This novel enzyme is particularly useful for screening candidate compounds for their ability to serve as potential anti-depressant, antiasthmatic or anti-inflammatory agents.

US Patent:

20020115111, Aug 22, 2002

Filed:

Feb 26, 2002

Appl. No.:

10/082985

Inventors:

Mary Barnette - West Chester PA, US
Theodore Torphy - Bryn Mawr PA, US
Siegfried Christensen - Philadelphia PA, US

Assignee:

SmithKline Beecham Corporation

International Classification:

A61K031/00
G01N033/53

US Classification:

435/007100, 514/001000

Abstract:

This invention relates to a method for selecting PDE IV inhibitors which have a salutory therapeutic index, and to compounds having these properties.

US Patent:

20030017150, Jan 23, 2003

Filed:

Mar 14, 2002

Appl. No.:

10/099007

Inventors:

Theodore Torphy - Bryn Mawr PA, US

International Classification:

A01K067/027
A61K039/395
C07K016/42
C07K016/40

US Classification:

424/131100, 800/014000, 530/387200, 530/388260

Abstract:

The present invention relates to at least one novel COPD-related human Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one COPD-related Ig derived protein or specified portion or variant, COPD-related Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

US Patent:

20030212112, Nov 13, 2003

Filed:

May 2, 2003

Appl. No.:

10/429666

Inventors:

Robert Murdoch - Harlow, GB
Theodore Torphy - Bryn Mawr PA, US
Barry Zussman - Welwyn, GB

Assignee:

SmithKline Beecham Corporation

International Classification:

A61K031/277
A61K031/4439

US Classification:

514/340000, 514/521000

Abstract:

This invention relates to a method for increasing the dose of a PDE4 inhibitor that can be administered at one time and be tolerated by the patient by reducing the absorption rate or the rate of rise in plasma concentration of the inhibitor.